Results 81 to 90 of about 56,101 (281)

Platelet reduction under hypoxia associated with GPIbα-vWF

open access: yes, 2023
Changes of platelet parameters in rats under chronic hypoxia;The changes of megakaryocyte number in bone marrow and lung tissue sections; The change of reticulated platelet proportion and platelet apoptosis; Effects of different oxygen concentrations on ...
Zhuoya Wang (16634874)   +1 more
core   +1 more source

Porcine kidney xenotransplantation: From primate models to clinical reality

open access: yesAnimal Models and Experimental Medicine, EarlyView.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo   +3 more
wiley   +1 more source

Maternal blood proteomics during relapse of early preeclampsia

open access: yesАкушерство, гинекология и репродукция
Aim: to study the contribution of maternal blood endothelial proteins to developing relapse of early preeclampsia (ePE).Materials and Methods. A proteomic analysis of the peripheral blood of 137 pregnant women was performed. Clinically, three groups were
M. G. Nikolaeva   +2 more
doaj   +1 more source

Reference intervals for active VWF and other VWF parameters in 120 healthy individuals.

open access: yes, 2019
Reference intervals for active VWF and other VWF parameters in 120 healthy individuals.
Jasper A. Remijn (6331226)   +8 more
core   +1 more source

A new Patient‐Reported Outcome Scale to assess autoimmune Encephalitis: PROSE

open access: yesAnnals of Neurology, EarlyView.
Objective Autoimmune encephalitis (AIE) has long‐lasting effects. Generic clinical assessment‐scales insufficiently capture disease‐specific sequelae. Patient‐reported outcome measures (PROMs) assess outcomes important to patients, ensuring relevance in the clinic and trials.
Juliette Brenner   +24 more
wiley   +1 more source

Biomimetic Nanoparticle Delivering Colchicine to Target Endothelial Inflammation for Atherosclerosis Treatment

open access: yesAdvanced NanoBiomed Research, EarlyView.
Platelet membrane‐coated layered double hydroxide nanoparticles were engineered to target inflamed endothelium at early‐stage atherosclerosis and enhance therapeutic efficacy. The biomimetic platform improves stability, immune escape, and inflamed vascular cell targeting, resulting in reduced oxidative stress and downregulated adhesion molecules.
Xiuwen Zhang   +4 more
wiley   +1 more source

Value of vWF-related indicators in the diagnosis of liver cirrhosis progression in patients with hepatitis B [PDF]

open access: yesZhenduanxue lilun yu shijian
Objective To evaluate the correlation between von Willebrand factor (vWF) and its related indicators and the progression of liver cirrhosis in patients with hepatitis B and explore the diagnostic value of vWF-related indicators in assisting the diagnosis
YANG Mingkang, LIU Yu, XU Guanqun, WANG Jianbiao, WANG Xuefeng, LIANG Qian
doaj   +1 more source

VWF springs into action [PDF]

open access: yesThe Journal of Cell Biology, 2006
![Graphic][1] Extended organelle form (left) is needed for later correct function. CUTLER/ELSEVIERFollowing blood vessel injury, long strings of multimeric von Willebrand's factor (VWF) act as a scaffold for platelets to help staunch bleeding. The VWF strings, 100-μm long or more,
openaire   +1 more source

vWF sequences

open access: yes, 2016
Nexus file containing phased alleles from vWF sequences of Sunda shelf Crocidura.
Handika, Heru   +13 more
core   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy